Literature DB >> 15015660

Stabilization of a progressive hemangioblastoma under treatment with thalidomide.

Maria Piribauer1, Thomas Czech, Karin Dieckmann, Peter Birner, Johannes A Hainfellner, Daniela Prayer, Barbara Fazeny-Dörner, Georg Weinländer, Christine Marosi.   

Abstract

After the second recurrence of spinal seeding in hemangioblastoma not associated to von-Hippel-Lindau disease, we treated an adult female patient with thalidomide 200 mg orally/day at night for longer than 1 year. The patient reported subjective relief of symptoms after 1 month. Magnetic resonance imaging (MRI) controls 1,6 and 11 months after begin of thalidomide treatment did not show further tumor progression. She remained wheelchair-bound, but mobility of her arms continuously improved. There was no thalidomide associated side-effect in this patient until her death from pneumonia due to legionnaire's disease. Antiangiogenic treatment with interferon (IFN) alpha-2a and IFN alpha-2b and with SU 5416 has been reported to be effective and well tolerated in several patients with previously progressive angioblastomas and hemangioblastomas. This case adds further evidence of the efficacy of an antiangiogenic treatment concept in a progressive hemangioblastoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15015660     DOI: 10.1023/b:neon.0000014493.88402.dc

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  26 in total

1.  Maintenance of vascular integrity in the embryo requires signaling through the fibroblast growth factor receptor.

Authors:  S H Lee; D J Schloss; J L Swain
Journal:  J Biol Chem       Date:  2000-10-27       Impact factor: 5.157

2.  Long-term prognosis of haemangioblastoma of the CNS: impact of von Hippel-Lindau disease.

Authors:  M Niemelä; S Lemeta; P Summanen; T Böhling; M Sainio; J Kere; K Poussa; R Sankila; H Haapasalo; H Kääriäinen; E Pukkala; J Jääskeläinen
Journal:  Acta Neurochir (Wien)       Date:  1999       Impact factor: 2.216

3.  Hemangioblastomas of the central nervous system. A 10-year study with special reference to von Hippel-Lindau syndrome.

Authors:  H P Neumann; H R Eggert; K Weigel; H Friedburg; O D Wiestler; P Schollmeyer
Journal:  J Neurosurg       Date:  1989-01       Impact factor: 5.115

Review 4.  Mechanisms of angiogenesis.

Authors:  W Risau
Journal:  Nature       Date:  1997-04-17       Impact factor: 49.962

5.  Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases.

Authors:  Jennifer J Marler; Joshua B Rubin; Nikolaus S Trede; Susan Connors; Holcombe Grier; Joseph Upton; John B Mulliken; Judah Folkman
Journal:  Pediatrics       Date:  2002-02       Impact factor: 7.124

Review 6.  New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF.

Authors:  J Holash; S J Wiegand; G D Yancopoulos
Journal:  Oncogene       Date:  1999-09-20       Impact factor: 9.867

7.  Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma.

Authors:  J E König; E Tolnay; T Wiethege; K M Müller
Journal:  Virchows Arch       Date:  1999-07       Impact factor: 4.064

8.  Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization.

Authors:  T Asahara; H Masuda; T Takahashi; C Kalka; C Pastore; M Silver; M Kearne; M Magner; J M Isner
Journal:  Circ Res       Date:  1999-08-06       Impact factor: 17.367

Review 9.  Potential novel uses of thalidomide: focus on palliative care.

Authors:  V Peuckmann; M Fisch; E Bruera
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

10.  WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients.

Authors:  C G Iyer; J Languillon; K Ramanujam; G Tarabini-Castellani; J T De las Aguas; L M Bechelli; K Uemura; V Martinez Dominguez; T Sundaresan
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

View more
  4 in total

1.  Erlotinib therapy for central nervous system hemangioblastomatosis associated with von Hippel-Lindau disease: a case report.

Authors:  Lisa R Rogers; Patricia LoRusso; Paul Nadler; Ghaus Malik; Anthony Shields; William Kaelin
Journal:  J Neurooncol       Date:  2010-06-04       Impact factor: 4.130

2.  Hemangioblastomatosis in a patient with von Hippel-Lindau disease.

Authors:  M C J Hanse; A Vincent; M J van den Bent
Journal:  J Neurooncol       Date:  2007-01-26       Impact factor: 4.130

3.  Disseminated cerebellar hemangioblastoma in two patients without von Hippel-Lindau disease.

Authors:  Jiro Akimoto; Hirokazu Fukuhara; Tomohiro Suda; Kenta Nagai; Ryo Hashimoto; Kohno Michihiro
Journal:  Surg Neurol Int       Date:  2014-10-07

4.  Brainstem hemangioblastoma and sellar mass.

Authors:  Chandan B Mohanty; Kvl Narasinga Rao; Somanna Sampath
Journal:  J Neurosci Rural Pract       Date:  2012-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.